Welcome to our dedicated page for brks news (Ticker: brks), a resource for investors and traders seeking the latest updates and insights on brks stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect brks's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of brks's position in the market.
Azenta, Inc. (Nasdaq: AZTA), formerly Brooks Automation, Inc. (Nasdaq: BRKS), announced the completion of its corporate name change on December 1, 2021, and will begin trading under the new ticker symbol AZTA. This change aligns with the launch of Azenta Life Sciences and follows the planned sale of its semiconductor automation business, expected to close in early 2022. Azenta aims to become a pure play life sciences company, focusing on cold-chain sample management and genomic services for the pharmaceutical and healthcare sectors.
Brooks Automation, trading as BRKS on Nasdaq, will participate in the Stephens Annual Investment Conference on December 3, 2021, starting at 1:00 p.m. CT. The event will be accessible via a live webcast on their investor relations website, with a replay available afterward. Brooks is transitioning to Azenta, Inc. and will change its ticker to AZTA on December 1, 2021. The company specializes in life sciences solutions and semiconductor automation, currently reporting the semiconductor division as discontinued operations due to a pending sale.
Brooks Automation (Nasdaq: BRKS) will participate in the Evercore ISI 4th Annual HealthCONx Virtual Conference on November 30, 2021, with a webcast starting at 2:40 p.m. ET. Interested investors can access the live event and replay through the investor relations website.
Brooks operates two primary businesses: Life Sciences and Semiconductor Solutions. The company is rebranding to Azenta, Inc. effective December 1, 2021, upon the divestiture of its Semiconductor Solutions Group.
Brooks Automation, Inc. (Nasdaq: BRKS) is rebranding to Azenta, Inc., effective December 1, 2021, when it will also change its Nasdaq ticker to AZTA. This decision follows the earlier announcement of its life sciences brand, Azenta Life Sciences, as part of its strategic shift towards a pure-play life sciences company after the expected divestiture of its Semiconductor Automation business in 2022. Shareholders do not need to take any action regarding this change.
Brooks Automation, Inc. (Nasdaq: BRKS) reported Q4 2021 revenue of $137 million, a 27% increase year-over-year, driven by strong growth in Life Sciences. Total diluted EPS was $0.29, reflecting a 25% decrease from 2020, while diluted loss per share from continuing operations was $0.30. For fiscal 2021, revenue rose 32% to $514 million. The company announced a pending divestiture of its Semiconductor Automation business and rebranded its Life Sciences sector as Azenta. Guidance for Q1 2022 expects revenue between $130 million and $140 million.
Brooks Automation, Inc. (Nasdaq: BRKS) announced a new contract with QTC Management, a Leidos company (NYSE: LDOS), to provide vaccine storage and distribution for the U.S. Department of Defense. This collaboration supports QTC's Reserve Health Readiness Program III, ensuring secure cold storage of vaccines and timely delivery across the U.S. and Germany. Azenta Life Sciences, the rebranded segment of Brooks, will leverage its expertise in cold-chain services to meet stringent requirements. This strategic move reflects Brooks' focus on expanding its Life Sciences business.
Brooks Automation, Inc. (Nasdaq: BRKS) will announce its fiscal 2021 fourth quarter and year-end earnings on November 10, 2021, after the market closes. A conference call to discuss the financial results will commence at 4:30 p.m. ET the same day. Analysts and investors can access the call by dialing 800-786-1918 for domestic and +1-212-231-2907 for international callers, or via a live webcast on the Brooks website. The company operates in two main sectors: Life Sciences and Semiconductor Solutions, with significant developments pending, including a sale of its Semiconductor Solutions Group.
Brooks Automation (Nasdaq: BRKS) announced the election of Frank Casal to its Board of Directors. Previously Vice Chair, Audit for KPMG, Casal brings over 40 years of experience in auditing and business leadership. His insight is expected to support Brooks as it enters a new transformative phase. The company, operating in Life Sciences and Semiconductor Solutions, is undergoing significant changes, including the impending sale of its Semiconductor Group to Thomas H. Lee Partners. Casal's appointment positions the company for enhanced strategic direction and governance.
Brooks Automation (Nasdaq: BRKS) announced the transition of Dr. Amy Liao, President of Life Sciences Services, to a strategic advisor role until year-end 2021, after which she will leave the company. Dr. Liao significantly contributed to the integration of GENEWIZ and the growth of the services business. Brooks is focusing on its new standalone life sciences entity, Azenta Life Sciences, which offers genomic services and cold-chain sample management for the pharmaceutical industry. The company is also selling its Semiconductor Solutions Group to Thomas H. Lee Partners.
